TLSA Tiziana Life Sciences Ltd.
Price Chart
Executive Summary
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 2026, with presentation at the ACTRIMS-ECTRIMS meeting in October 2026. This milestone de-risks the program and brings the company closer to a pivotal readout for a novel, non-invasive anti-CD3 therapy.
Actionable Insight
Traders should watch for topline data in late Q3 2026 and the ACTRIMS-ECTRIMS presentation in October 2026. Positive results could drive a re-rating given the limited treatment options for na-SPMS and the novel mechanism. Monitor for any safety signals or early efficacy trends from the OLE data.
Key Facts
- Completed enrollment of 48 patients in Phase 2a randomized, double-blind, placebo-controlled trial (INFORM-MS) of intranasal foralumab for na-SPMS.
- Topline data expected in late Q3 2026; results to be presented at ACTRIMS-ECTRIMS meeting in Toronto, October 2026.
- Trial includes 12-week blinded treatment period followed by a 6-month open-label extension for all participants.
- Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, targeting neuroinflammation via a novel non-invasive route.
- Prior open-label Expanded Access Program (n=14) showed improvement or stability in all patients within 6 months.
Financial Impact
No financial data provided; clinical milestone with potential to unlock significant value if topline data is positive. Market cap ~$205M.
Risk Factors
- Phase 2a trial may fail to meet primary or secondary endpoints, leading to significant downside.
- Competition from existing and emerging SPMS therapies (e.g., siponimod, ocrelizumab).
- Regulatory and manufacturing risks for intranasal biologic delivery.
- Company is pre-revenue with no approved products; relies on capital markets for funding.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 15, 2026
3d ago
|
6-K
| $1.11 $1.10 | ▼ −0.90% | ▼ −0.30% | $1.08 (−2.70%) |
|
May 28, 2026
21d ago
|
6-K
| $1.46 $1.41 | ▼ −3.42% | ▼ −3.66% | $1.08 (−26.03%) |
|
May 21, 2026
28d ago
|
6-K
| $1.46 $1.48 | ▲ +1.37% | ▲ +0.92% | $1.08 (−26.03%) |
|
May 21, 2026
28d ago
|
Press Release
| $1.46 $1.48 | ▲ +1.37% | ▲ +0.92% | $1.08 (−26.03%) |
|
May 19, 2026
4w ago
|
6-K
| $1.38 $1.61 | ▲ +16.67% | ▲ +15.63% | $1.08 (−21.74%) |
|
May 14, 2026
5w ago
|
6-K
| $1.45 $1.37 | ▼ −5.52% | ▼ −4.29% | $1.08 (−25.52%) |
|
Apr 16, 2026
9w ago
|
6-K
| $1.34 $1.24 | ▼ −7.46% | ▼ −8.68% | $1.08 (−19.40%) |
|
Apr 16, 2026
9w ago
|
Press Release
| $1.34 $1.24 | ▼ −7.46% | ▼ −8.68% | $1.08 (−19.40%) |
|
Apr 14, 2026
9w ago
|
6-K
| $1.29 $1.33 | ▲ +3.10% | ▲ +2.33% | $1.08 (−16.28%) |
|
Apr 14, 2026
9w ago
|
Press Release
| $1.29 $1.33 | ▲ +3.10% | ▲ +2.33% | $1.08 (−16.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access